Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Delcath Systems Inc DCTH

Healthcare Medical Devices Diagnostics & Research
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while... see more

Recent & Breaking News (NDAQ:DCTH)

DELCATH TO REPORT FIRST QUARTER 2013 RESULTS ON MAY 8, 2013

Thomson Reuters ONE May 1, 2013

DELCATH ANNOUNCES POSTING OF BRIEFING DOCUMENTS FOR FDA ONCOLOGIC DRUGS ADVISORY COMMITTEE MEETING ON MELBLEZTM KIT

Thomson Reuters ONE April 30, 2013

Free Research Reports on ABIO, DCTH, MUX and XIDE Issued by the Bedford Report

Marketwired April 23, 2013

Free Research Reports on AFFX, BMC, DCTH and TSL Issued by the Paragon Report

Marketwired April 10, 2013

Hospira, Delcath Systems, Valeant Pharma, and Alkermes Under StockCall's Microscope

PR Newswire April 9, 2013

DELCATH EXPANDS PROGRAM TO INCREASE EFFICIENCIES AND REDUCE CASH UTILIZATION

Thomson Reuters ONE April 8, 2013

Free Research Reports on BLRX, DCTH, WNR and XONE Issued by the Bedford Report

Marketwired April 8, 2013

Free Research Reports on DCTH, SIGM, SVA and WPX Issued by the Bedford Report

Marketwired March 15, 2013

DELCATH TO PRESENT AT ROTH CONFERENCE ON MARCH 18, 2013

Thomson Reuters ONE March 15, 2013

DELCATH REPORTS FOURTH QUARTER AND FULL YEAR 2012 RESULTS

Thomson Reuters ONE March 13, 2013

Morning Research on Valeant Pharma Intl., Hospira, Delcath Systems, and Alkermes

PR Newswire March 11, 2013

DELCATH TO REPORT FOURTH QUARTER AND FULL YEAR 2012 RESULTS ON MARCH 13, 2013

Thomson Reuters ONE February 28, 2013

DELCATH TO PRESENT AT COWEN AND COMPANY HEALTHCARE CONFERENCE ON MARCH 4, 2013

Thomson Reuters ONE February 27, 2013

DELCATH ANNOUNCES ODAC MEETING REVIEW DATE FOR ITS PROPRIETARY DRUG/DEVICE COMBINATION PRODUCT DELCATH HEPATIC DELIVERY SYSTEM

Thomson Reuters ONE February 27, 2013

Free Research Reports on APPY, ATHX, CLSN and DCTH Issued by the Bedford Report

Marketwired February 5, 2013

Free Research Report on Pike Electric Corp., DARA Biosciences, Inc., Deutsche Bank Niamen AKT, Delcath Systems, Inc. and Dollar General Corp.

PR Newswire January 31, 2013

Delcath Systems Under StockCall Microscope: Will This Drug Delivery System's Stocks Rebound This Year?

PR Newswire January 30, 2013

Monday's Most Active -- RAD, GSS, CLSN and DCTH

Marketwired December 26, 2012